Outlook Therapeutics, Inc.
Outlook Therapeutics (Nasdaq: OTLK) said it will release its third quarter fiscal 2026 financial results and hold a corporate update call and webcast on Aug. 14, 2026 at 8:30 AM ET. The call will be led by CEO Bob Jahr and CFO Lawrence A. Kenyon. The webcast will be available on the company’s investor events page.
Zacks says Outlook Therapeutics (OTLK) is set to report Q3 earnings. It cites an Earnings ESP of +42.31% and a Zacks Consensus loss estimate of 9 cents versus a most accurate estimate loss of 5 cents, with a Zacks Rank of #3. The article also mentions HRMY, ACAD, and ARQT earnings setups.
The healthcare sector saw multiple company-specific moves. Pfizer and BioNTech received EU approval for an updated COVID-19 vaccine targeting the XFG variant. Cipla won FDA approval for generic Advair Diskus, and Viatris gained FDA approval for its Gwyn Lo contraceptive patch. AbbVie’s Rinvoq was approved in the EU for non-segmental vitiligo. Boston Scientific announced an $800M restructuring plan, while GSK launched a $2.5B cost-saving program. J&J and Sail agreed a $3.51B CAR-T deal; Argenx ac
Over the past 7 days, alphai's AI scored 2 news stories mentioning OTLK (Outlook Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent OTLK coverage spans regulation, financial news and earnings.
In the last 30 days, OTLK insiders filed 1 SEC Form 4 transaction — 1 purchase ($100K) and no sales. The most active reporter was Sukhtian Faisal Ghiath with 1 filing.
This is a scheduled earnings and corporate update event that can drive volatility around guidance, cash runway, and commercial traction for LYTENAVA.
This is a pre-earnings positioning piece, not a new fundamental disclosure beyond consensus loss and the model’s beat odds.
First FDA approval for a regulated ophthalmic bevacizumab formulation is a meaningful commercialization milestone.
FDA approval is a direct commercialization catalyst, with exclusivity and a planned end-2026 U.S. launch shaping near-term valuation expectations.
A routine insider open-market purchase provides mild sentiment support but no new operational or financial catalyst.
alphai scores every news story that mentions OTLK with an AI model for sentiment and relevance, and aggregates insider trades from Outlook Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Outlook Therapeutics (Nasdaq: OTLK) said it will release its third quarter fiscal 2026 financial results and hold a corporate update call and webcast on Aug. 14, 2026 at 8:30 AM ET. The call will be led by CEO Bob Jahr and CFO Lawrence A. Kenyon. The webcast will be available on the company’s investor events page.
2 min readZacks says Outlook Therapeutics (OTLK) is set to report Q3 earnings. It cites an Earnings ESP of +42.31% and a Zacks Consensus loss estimate of 9 cents versus a most accurate estimate loss of 5 cents, with a Zacks Rank of #3. The article also mentions HRMY, ACAD, and ARQT earnings setups.
3 min readThe healthcare sector saw multiple company-specific moves. Pfizer and BioNTech received EU approval for an updated COVID-19 vaccine targeting the XFG variant. Cipla won FDA approval for generic Advair Diskus, and Viatris gained FDA approval for its Gwyn Lo contraceptive patch. AbbVie’s Rinvoq was approved in the EU for non-segmental vitiligo. Boston Scientific announced an $800M restructuring plan, while GSK launched a $2.5B cost-saving program. J&J and Sail agreed a $3.51B CAR-T deal; Argenx ac
7 min readThe U.S. retina care market continues to draw attention from life sciences investors as new treatments address wet age-related macular degeneration, a leading cause of vision loss in older adults. Outlook Therapeutics Inc. (OTLK:NASDAQ) now stands at the center of this opportunity after securing regulatory clearance for its lead candidate. Market Opportunity in Retina Care Wet age-related macular degeneration damages central vision through abnormal blood vessel growth under the retina.
6 min readSukhtian Faisal Ghiath purchased 95,398 shares of Outlook Therapeutics, Inc. (OTLK) at $1.05 on 2026-07-29.
2 min readOutlook Therapeutics said the FDA approved LYTENAVA, an ophthalmic bevacizumab formulation for wet AMD, after three prior FDA rejections. The company expects 12 years of reference product exclusivity and plans a commercial rollout, with eligible patients expected to access it before year-end. Outlook Therapeutics shares were down 9.60% to $1.27.
5 min readOutlook Therapeutics (OTLK) shares rose about 8.9% pre-open after the FDA approved LYTENAVA (bevacizumab-vikg) for neovascular age-related macular degeneration, arriving July 24 ahead of the July 29 PDUFA date. BTIG upgraded to Buy and set a $4.00 target. Consensus 12-month target is $5.50. The company also regained Nasdaq bid compliance and LYTENAVA is authorized in parts of Europe.
4 min readOutlook Therapeutics (OTLK) said the FDA approved LYTENAVA, an ophthalmic bevacizumab formulation for neovascular age-related macular degeneration. The company said it is purpose-built for intravitreal use and grants 12 years of market exclusivity. OTLK shares closed at $1.40, up 6.44% on Friday.
3 min readOutlook Therapeutics, Inc. (OTLK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001649989 0001649989 2026-07-21 2026-07-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
3 min readOutlook Therapeutics, Inc. (OTLK) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false --09-30 0001649989 0001649989 2026-07-16 2026-07-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date
4 min read
